A Study to Assess the Relative Bioavailability of Two Formulations of Risankizumab Following Subcutaneous Administration With Prefilled Syringes in Healthy Adult Participants

Inclusion Criteria:

• Body weight 40 kg to 100 kg, inclusive, at screening and upon initial confinement

• Body Mass Index (BMI) is > = 18.0 to < = 32.0 kg/m2 after rounded to the tenthsdecimal, at Screening and upon confinement.

• A condition of general good health, based upon the results of a medical history,physical examination, vital signs, laboratory profile and a 12-lead ECG.

Exclusion Criteria:

• Participant with exposure to any anti-interleukin-12/23 or anti-interleukin-23treatment for at least one year prior to Screening.

• Participant with intention to perform strenuous exercise within at least one weekprior to administration of study drug or during the study.

• History of epilepsy, any clinically significant cardiac, respiratory (except mildasthma as a child), renal, hepatic, gastrointestinal, hematologic or psychiatricdisease or disorder, or any uncontrolled medical illness.